A comparative study of ceftazidime/avibactam-based and fosfomycin plus meropenem-based regimens for managing infections caused by carbapenem-resistant < em > Klebsiella pneumoniae < /em > in critically ill patients
J Chemother. 2024 May 3:1-9. doi: 10.1080/1120009X.2024.2349439. Online ahead of print.ABSTRACTThe main aim of this study was to compare and analyze the effectiveness of treatment regimens using ceftazidime/avibactam (CAZ/AVI) versus fosfomycin plus meropenem (FOS/MER) for managing bloodstream infections (BSI) or ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) in critically ill patients. Between 4 January 2019, and 16 July 2023, adult patients (≥18 years old) diagnosed with BSI or VAP due to culture confirmed CRKP in ICU of a tertiary care hospital were investigated retro...
Source: Journal of Chemotherapy - May 3, 2024 Category: Cancer & Oncology Authors: U ğur Önal Ülkü Tüzemen P ınar Küçükdemirci Kaya Remzi İşçimen Nermin Kelebek Girgin C üneyt Özakın Ferda Kahveci Halis Akal ın Source Type: research
Predictors of olaparib discontinuation owing to adverse drug events in patients with ovarian, peritoneal, or fallopian tube cancer: a retrospective observational study
J Chemother. 2024 May 2:1-7. doi: 10.1080/1120009X.2024.2345025. Online ahead of print.ABSTRACTWe investigated predictors of olaparib discontinuation owing to adverse effects. Patients with ovarian, peritoneal, or fallopian tube cancers treated with olaparib at Osaka Medical and Pharmaceutical University Hospital between April 2018 and September 2022 were included in this study. The exclusion criteria were as follows: discontinuation of treatment due to disease progression, use of anaemia medications, and use of cytochrome P450 (CYP3A4) inhibitors. The follow-up period was 90 d. Of the 46 eligible patients, 21 patients dis...
Source: Journal of Chemotherapy - May 2, 2024 Category: Cancer & Oncology Authors: Noriaki Kataoka Takeo Hata Kouichi Hosomi Atsushi Hirata Satoe Fujiwara Emi Goto Masami Nishihara Masahide Ohmichi Masashi Neo Source Type: research
Differential synergistic effects of palbociclib and doxorubicin on doxorubicin-resistant cancer cells with diverse tumor origins
J Chemother. 2024 Apr 25:1-9. doi: 10.1080/1120009X.2024.2345454. Online ahead of print.ABSTRACTPalbociclib is a dual inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Palbociclib has frequently been studied in breast cancer cells and has also been linked to function of P-glycoprotein (P-gp), main protein responsible for cancer drug resistance. However, the effect of Palbociclib on cancer drug resistance and specifically doxorubicin-resistant cells overexpressing P-gp have limitedly been studied in the literature. Here, we aimed to decipher the possible synergistic effects of Palbociclib and Doxorubicin combination t...
Source: Journal of Chemotherapy - April 26, 2024 Category: Cancer & Oncology Authors: Gizem Damla Yalcin Pelin Mutlu Hasan Huseyin Kazan Ufuk Gunduz Source Type: research
Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with < em > Staphylococcus Aureus < /em > by pharmacokinetic/pharmacodynamic analysis
J Chemother. 2024 Apr 22:1-8. doi: 10.1080/1120009X.2024.2343963. Online ahead of print.ABSTRACTOmadacycline is an FDA-approved agent for community-acquired bacterial pneumonia (CABP). The purpose of this study is to evaluate the effectiveness of omadacycline for treating CABP patients infected with Staphylococcus aureus, including Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Susceptible Staphylococcus aureus (MSSA), using pharmacokinetic/pharmacodynamic (PK/PD) analysis. Monte Carlo simulations (MCSs) were performed by utilizing omadacycline pharmacokinetic (PK) parameters, minimum inhibitory concent...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Gaoqi Xu Xin Liu Jiaqi Wang Yuqing Mei Dihong Yang Chaoneng He Like Zhong Junfeng Zhu Haiying Ding Luo Fang Source Type: research
Long-term remission after upfront autologous hematopoietic stem cell transplant for CD5 < sup > + < /sup > diffuse large-B cell lymphoma
J Chemother. 2024 Apr 23:1-9. doi: 10.1080/1120009X.2024.2340147. Online ahead of print.ABSTRACTCD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype characterized by an inferior outcome. While dose-dense therapy shows promising activity, the optimal management remains to be determined. To evaluate the benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT), we retrospectively reviewed the medical records of 47 consecutive patients with newly diagnosed de novo CD5+ DLBCL. Of 19 patients ≤ 70 of age with age-adjusted International Prognostic Index 2-3, eight underwent upfront ASCT, and ni...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Yosuke Masamoto Akira Honda Aya Shinozaki-Ushiku Tetsuo Ushiku Mineo Kurokawa Source Type: research
Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with < em > Staphylococcus Aureus < /em > by pharmacokinetic/pharmacodynamic analysis
J Chemother. 2024 Apr 22:1-8. doi: 10.1080/1120009X.2024.2343963. Online ahead of print.ABSTRACTOmadacycline is an FDA-approved agent for community-acquired bacterial pneumonia (CABP). The purpose of this study is to evaluate the effectiveness of omadacycline for treating CABP patients infected with Staphylococcus aureus, including Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Susceptible Staphylococcus aureus (MSSA), using pharmacokinetic/pharmacodynamic (PK/PD) analysis. Monte Carlo simulations (MCSs) were performed by utilizing omadacycline pharmacokinetic (PK) parameters, minimum inhibitory concent...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Gaoqi Xu Xin Liu Jiaqi Wang Yuqing Mei Dihong Yang Chaoneng He Like Zhong Junfeng Zhu Haiying Ding Luo Fang Source Type: research
Long-term remission after upfront autologous hematopoietic stem cell transplant for CD5 < sup > + < /sup > diffuse large-B cell lymphoma
J Chemother. 2024 Apr 23:1-9. doi: 10.1080/1120009X.2024.2340147. Online ahead of print.ABSTRACTCD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype characterized by an inferior outcome. While dose-dense therapy shows promising activity, the optimal management remains to be determined. To evaluate the benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT), we retrospectively reviewed the medical records of 47 consecutive patients with newly diagnosed de novo CD5+ DLBCL. Of 19 patients ≤ 70 of age with age-adjusted International Prognostic Index 2-3, eight underwent upfront ASCT, and ni...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Yosuke Masamoto Akira Honda Aya Shinozaki-Ushiku Tetsuo Ushiku Mineo Kurokawa Source Type: research
Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with < em > Staphylococcus Aureus < /em > by pharmacokinetic/pharmacodynamic analysis
J Chemother. 2024 Apr 22:1-8. doi: 10.1080/1120009X.2024.2343963. Online ahead of print.ABSTRACTOmadacycline is an FDA-approved agent for community-acquired bacterial pneumonia (CABP). The purpose of this study is to evaluate the effectiveness of omadacycline for treating CABP patients infected with Staphylococcus aureus, including Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Susceptible Staphylococcus aureus (MSSA), using pharmacokinetic/pharmacodynamic (PK/PD) analysis. Monte Carlo simulations (MCSs) were performed by utilizing omadacycline pharmacokinetic (PK) parameters, minimum inhibitory concent...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Gaoqi Xu Xin Liu Jiaqi Wang Yuqing Mei Dihong Yang Chaoneng He Like Zhong Junfeng Zhu Haiying Ding Luo Fang Source Type: research
Long-term remission after upfront autologous hematopoietic stem cell transplant for CD5 < sup > + < /sup > diffuse large-B cell lymphoma
J Chemother. 2024 Apr 23:1-9. doi: 10.1080/1120009X.2024.2340147. Online ahead of print.ABSTRACTCD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype characterized by an inferior outcome. While dose-dense therapy shows promising activity, the optimal management remains to be determined. To evaluate the benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT), we retrospectively reviewed the medical records of 47 consecutive patients with newly diagnosed de novo CD5+ DLBCL. Of 19 patients ≤ 70 of age with age-adjusted International Prognostic Index 2-3, eight underwent upfront ASCT, and ni...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Yosuke Masamoto Akira Honda Aya Shinozaki-Ushiku Tetsuo Ushiku Mineo Kurokawa Source Type: research
